Celladon Corp.

Celladon aims to reverse the downhill spiral of cardiomyocyte damage in heart failure. Its first product is a form of gene therapy, delivered by a recombinant adeno-associated viral vector, designed to augment SERCA2a-mediated calcium transport in HF patients. The SERCA2a pathway is pivotal in controlling the heart's pumping ability, and numerous studies have correlated heart failure progression with declines in SERCA2a levels.